Sinolink: Several central and state-owned enterprises in the building materials sector, including Beixin and Kaisheng, have released incentive plans that emphasize the direction of Market Cap management.

From the action plans of state-owned and centrally administered enterprises that are being progressively implemented, the overall process has accelerated, reflecting the confidence of central enterprises in high-quality development and operational capabilities, and it is expected to play a leading role in specific segments of the Industry.

Zhitong FinanceJan 3 10:43

Express News | Shandong Pharmaceutical Glass: The controlling shareholder is planning a restructuring.

BreakingsDec 31, 2024 15:35

Debon Securities: The scale of borosilicate pharmaceutical glass is continuously expanding. Pay attention to the improvement in industry profitability as costs decline.

The national centralized procurement promotes the use of medium borosilicate packaging for pharmaceuticals, expanding the market size of medium borosilicate pharmaceutical glass.

Zhitong FinanceDec 5, 2024 15:40

shandong pharmaceutical glass (600529): The leader in the pharmaceutical glass industry benefits from both the cost reduction of policy dividends.

With a focus on pharmaceutical glass for fifty years, Shandong Pharmaceutical Glass, a comprehensive provider of pharmaceutical packaging materials including "bottles + stoppers + caps", originated from the Shandong Provincial Pharmaceutical Glass Factory, which was established in 1970, and has a history of over fifty years in pharmaceutical glass production. The company has evolved from initially producing ampoules to now...

Chengtong SecuritiesDec 2, 2024 00:00

Shandong pharmaceutical glass (600529.SH): The company's production lines are basically running at full capacity.

Glory Network announced on November 27 that shandong pharmaceutical glass (600529.SH) stated on the investor interaction platform that the company's production lines are mostly running at full capacity; the existing production capacity of pre-filled products can meet market demand, and the delay of the 0.56 billion pre-filled syringe annual production expansion and renovation project has no substantial impact on the company's production and performance.

Gelonghui FinanceNov 27, 2024 17:39

Shandong Pharmaceutical Glass (600529.SH): The fundraising project, 'Expansion and renovation project to increase the production capacity of 0.56 billion pre-filled syringes per year,' has been postponed to December 31, 2025.

Grain Dynamics November 25th | Shandong Pharmaceutical Glass (600529.SH) announced that the company held the fifteenth meeting of the tenth board of directors and the thirteenth meeting of the tenth board of supervisors on November 25, 2024. It reviewed and passed the proposal on the extension of the project of expanding and renovating the production of 0.56 billion pre-filled syringes annually among the company's investment projects, agreeing that the completion time of the investment project "expansion and renovation of the production capacity of 0.56 billion pre-filled syringes annually" would be extended from December 31, 2024.

Gelonghui FinanceNov 25, 2024 15:36